RecruitingPhase 3NCT07166406
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
Studying Adult hepatocellular carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- NRG Oncology
- Intervention
- Atezolizumab(biological)
- Enrollment
- 252 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2029
Study locations (30)
- Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, United States
- Palo Alto Medical Foundation-Fremont, Fremont, California, United States
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
- Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
- Palo Alto Medical Foundation Health Care, Palo Alto, California, United States
- Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California, United States
- Sutter Roseville Medical Center, Roseville, California, United States
- Sutter Medical Center Sacramento, Sacramento, California, United States
- California Pacific Medical Center-Pacific Campus, San Francisco, California, United States
- Sutter Pacific Medical Foundation, Santa Rosa, California, United States
- Palo Alto Medical Foundation-Sunnyvale, Sunnyvale, California, United States
- Saint Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States
- Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07166406 on ClinicalTrials.govOther trials for Adult hepatocellular carcinoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE2NCT07441369Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases CancerFudan University
- RECRUITINGPHASE2NCT07175441Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular CarcinomaRiboscience, LLC.
- RECRUITINGPHASE2NCT07560488Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular CarcinomaTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE1, PHASE2NCT07291076A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)Bristol-Myers Squibb
- RECRUITINGPHASE2NCT07010497A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular CarcinomaAsan Medical Center
- RECRUITINGPHASE1, PHASE2NCT07500220Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCCBeijing Biotech
- RECRUITINGPHASE2NCT07413354Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular CarcinomaTongji Hospital
- RECRUITINGNANCT07365527Sonoporation and Tumor Microenvironment Response in Colorectal Liver MetastasesZealand University Hospital